Verrica Pharmaceuticals (1NE0) Financial Statements
Verrica Pharmaceuticals Financial Overview
Verrica Pharmaceuticals's market cap is currently $51.36M. The company's EPS TTM is $-1.74; its P/E ratio is -1.93; Verrica Pharmaceuticals is scheduled to report earnings on November 9, 2026, and the estimated EPS forecast is $-0.44. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 35.58M | $ 7.57M | $ 5.12M | $ 9.03M | $ 12.00M |
| Gross Profit | $ 32.14M | $ 4.83M | $ 4.38M | $ 8.31M | $ 11.53M |
| Operating Income | $ -11.94M | $ -65.92M | $ -65.76M | $ -21.30M | $ -30.91M |
| EBITDA | $ -9.36M | $ -65.90M | $ -62.20M | $ -21.60M | $ -30.31M |
| Net Income | $ -17.89M | $ -76.58M | $ -67.00M | $ -24.49M | $ -35.08M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 30.15M | $ 46.33M | $ 69.55M | $ 34.27M | $ 70.35M |
| Total Assets | $ 47.13M | $ 54.13M | $ 81.60M | $ 44.72M | $ 80.13M |
| Total Debt | $ 1.63M | $ 45.94M | $ 45.51M | $ 1.53M | $ 43.41M |
| Net Debt | $ -28.52M | $ -390.00K | $ -24.04M | $ -32.75M | $ 27.66M |
| Total Liabilities | $ 22.39M | $ 63.99M | $ 61.83M | $ 4.69M | $ 47.52M |
| Stockholders' Equity | $ 24.74M | $ -9.86M | $ 19.76M | $ 40.03M | $ 32.60M |
| Cash Flow | |||||
| Free Cash Flow | $ -17.63M | $ -60.95M | $ -38.94M | $ -18.95M | $ -28.46M |
| Operating Cash Flow | $ -17.63M | $ -60.93M | $ -38.58M | $ -18.65M | $ -27.58M |
| Investing Cash Flow | $ 0.00 | $ -19.00K | $ -362.00K | $ 54.04M | $ -998.00K |
| Financing Cash Flow | $ 1.45M | $ 37.73M | $ 74.21M | $ -16.87M | $ 33.65M |
Currency in USD